RAYMOND JAMES & ASSOCIATES - INTERCEPT PHARMACEUTICALS IN ownership

INTERCEPT PHARMACEUTICALS IN's ticker is and the CUSIP is 45845PAA6. A total of 24 filers reported holding INTERCEPT PHARMACEUTICALS IN in Q1 2022. The put-call ratio across all filers is - and the average weighting 0.1%.

Quarter-by-quarter ownership
RAYMOND JAMES & ASSOCIATES ownership history of INTERCEPT PHARMACEUTICALS IN
ValueSharesWeighting
Q1 2023$138,625
+1.0%
140,0000.0%0.00%
Q4 2022$137,204
-40.6%
140,000
-41.7%
0.00%
Q3 2022$231,000
+0.4%
240,0000.0%0.00%
Q2 2022$230,000
+5.0%
240,0000.0%0.00%
Q1 2022$219,000
-3.1%
240,0000.0%0.00%
Q4 2021$226,000
-5.0%
240,000
-9.4%
0.00%
Q3 2021$238,0000.0%265,0000.0%0.00%
Q2 2021$238,000
-0.8%
265,000
-10.2%
0.00%
Q1 2021$240,000
+5.7%
295,0000.0%0.00%
Q4 2020$227,000
-50.4%
295,000
-48.2%
0.00%
-100.0%
Q3 2020$458,000
-5.0%
570,000
-10.9%
0.00%0.0%
Q2 2020$482,000
-7.3%
640,000
-1.5%
0.00%0.0%
Q1 2020$520,000
-21.8%
650,000
-1.5%
0.00%0.0%
Q4 2019$665,000
+14.5%
660,000
-2.2%
0.00%0.0%
Q3 2019$581,000
+837.1%
675,000
+864.3%
0.00%
Q2 2019$62,000
+26.5%
70,000
+40.0%
0.00%
Q1 2019$49,000
+6.5%
50,0000.0%0.00%
Q4 2018$46,000
-9.8%
50,0000.0%0.00%
Q3 2018$51,00050,0000.00%
Other shareholders
INTERCEPT PHARMACEUTICALS IN shareholders Q1 2022
NameSharesValueWeighting ↓
DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) 57,791,000$56,098,0001.12%
L & S Advisors Inc 795,000$767,0000.14%
OAKTREE CAPITAL MANAGEMENT LP 9,964,000$9,690,0000.11%
WEDBUSH SECURITIES INC 13,000$1,251,0000.07%
Kohlberg Kravis Roberts & Co. L.P. 3,163,000$3,076,0000.06%
ZAZOVE ASSOCIATES LLC 246,000$240,0000.02%
Balboa Wealth Partners 21,000$200.01%
Russell Investments Group, Ltd. 1,910,000$1,875,0000.00%
GAMCO INVESTORS, INC. ET AL 250,000$244,0000.00%
Regal Investment Advisors LLC 20,000$19,0000.00%
View complete list of INTERCEPT PHARMACEUTICALS IN shareholders